“Medication or lifestyle?” is one of the most common framings in obesity and diabetes care, and it is usually a false choice. A large study published in The Lancet Diabetes & Endocrinology in February 2026 tested the “and” version of the question, and its results are worth reading closely, including the parts that limit what it can tell you.
What the researchers did
The team used the US Veterans Affairs Million Veteran Program to follow more than 98,000 adults with type 2 diabetes and no history of cardiovascular disease, from 2011 through 2023. About 13,000 of them used a GLP-1 receptor agonist. Over roughly 632,000 person-years of follow-up, just over 10,000 people had a major adverse cardiovascular event: a nonfatal heart attack, a nonfatal stroke, or death from cardiovascular causes.
Each participant also got a lifestyle score of 0 to 8, one point for each of eight low-risk habits: a higher-quality diet, being physically active, not smoking, restful sleep, no heavy alcohol use, good stress management, social connection, and no opioid use disorder.
What they found
Reported as hazard ratios, where 1.0 would mean no difference in risk:
- People who met all eight habits had a lower rate of major cardiovascular events than people who met one or none: an adjusted hazard ratio of 0.40 (95% CI 0.30–0.54).
- GLP-1 use on its own was associated with roughly 16% lower risk than non-use.
- The two together did better than either alone. Comparing people using a GLP-1 who had six to eight habits against people not using one who had three or fewer, the reported reduction was about 43%.
The headline the authors drew is reasonable: medication and daily habits appear to add to each other rather than compete. It also fits the direction of other work, including the Endocrine Society’s push to judge these medications on more than the scale.
What the study does not establish
It is observational. Nobody was assigned to a lifestyle or a drug. People who sleep well, exercise, and keep social ties differ from people who don’t in ways no statistical adjustment fully removes: income, health literacy, access to care, how sick they were to begin with. The authors adjusted for many of these, but residual confounding is a standing limitation of this design.
Lifestyle was self-reported. In the earlier conference version of this work, the habits came from survey answers rather than measured behavior. People tend to over-report healthy habits, and that error is not evenly spread.
Habits and health can run in both directions. Someone with early, unrecognized illness may sleep worse or move less. That can make a healthy habit look protective when it is partly a marker of who was already well.
The population is narrow. The cohort was mostly white male veterans, though the authors report findings held across racial and ethnic groups and between men and women. All had type 2 diabetes. The study did not look at people using these medications for weight management, so its numbers are not a forecast for that group.
Percentages of relative risk are not your risk. A 43% relative reduction applies to a group average and says nothing about what would happen to any one person. The figures also moved between the conference abstract, which used a smaller sample, and the final paper, a reminder that early numbers are provisional.
The part that applies to compounded medications
The GLP-1 use in this study was prescriptions for branded, manufactured medications in people with diabetes. It says nothing about compounded preparations.
Compounded semaglutide and tirzepatide are prepared by state-licensed 503A pharmacies for an individual patient. They are not FDA-approved, and this study did not examine them. If anyone uses it to suggest a compounded product lowers your cardiovascular risk, they are stretching it past what it covers.
What is reasonable to take from it
Read narrowly, the study supports something modest and useful: a medication appointment is not the whole plan. Of the eight habits on that list, sleep is one you can actually measure. If you snore, wake unrefreshed, or have never been checked, an at-home Happy Sleep study can put a number on it instead of leaving it a guess.
If you are weighing a provider-guided program, how it works explains the steps and who makes each decision. Whether any medication is appropriate for you is a clinical question for a licensed provider, not something a cohort study can answer.
This post is general information, not medical advice. It does not describe a benefit of any NoBsRx program, and it is not a claim that any medication or habit will lower your cardiovascular risk. Compounded medications are not FDA-approved. Treatment is never guaranteed. Eligibility and every treatment decision are made by independent licensed providers based on an individual clinical assessment, and availability varies by state. Do not start, stop, or change any treatment based on an article. If you have questions about your heart health, talk to a licensed clinician.